Loading patent…
AssigneeMeiji Dairies Corporation
InventorsYoshinori Asakawa, Sachiko Okabe, Masashi Yamada, Yukie Suma, Hiroto Suzuki, Masayuki Uchida, Natsuko Murata
Estimating the term…
The present invention provides a TNF-α production inhibitor containing a kavalactone as an active ingredient, which inhibitor has high safety, exerts an excellent effect of inhibiting TNF-α production, and is useful as a drug or an animal drug for preventing, ameliorating, or treating diseases such as cachexia attributed to cancer or infectious diseases, chronic rheumatoid arthritis, inflammatory diseases, osteoarthritis, systemic lupus erythematosus (SLE), rejection during bone marrow transplantation, multiple organ failure, AIDS, meningitis, hepatitis, and type-II diabetes. The present invention also provides a preventive, ameliorating, or therapeutic agent for diseases caused by abnormal production of TNF-α, the agent containing a kavalactone as an active ingredient.
A TNF-α production inhibitor comprising a kavalactone as an active ingredient.
A preventive, ameliorating, or therapeutic agent comprising a kavalactone as an active ingredient for diseases caused by abnormal production of TNF-α.
A method for the treatment of diseases caused by abnormal production of TNF-α, which method comprises administering an effective amount of a kavalactone.
Use of a kavalactone for the manufacture of a TNF-α production inhibitor.
Use of a kavalactone for the manufacture of a medicament for preventing, ameliorating, or treating diseases caused by abnormal production of TNF-α.
Dependencies are inferred from the claim text.